 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...7891011121314151617...2425» |
- | Leukine (sargramostim) / Partner Therap
Enrollment closed: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (clinicaltrials.gov) - Jan 9, 2019
P2, N=203, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap, Danyelza (naxitamab) - Y / mAbs Therap
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: Study of Chemoimmunotherapy for High-Risk Neuroblastoma (clinicaltrials.gov) - Jan 7, 2019
P2, N=36, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Phase classification: P1 --> P2 | N=20 --> 36 | Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Jan 7, 2019
P2, N=95, Not yet recruiting, Sponsor: Children's Oncology Group
- || biropepimut-S (GL-0817) / Gliknik
Trial completion date, Trial primary completion date: Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - Jan 4, 2019
P2, N=80, Recruiting, Sponsor: Gliknik Inc.
Phase classification: P1 --> P2 | N=20 --> 36 | Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2020 --> Jun 2021
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed, Trial primary completion date, Combination therapy: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (clinicaltrials.gov) - Jan 2, 2019
P2, N=44, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2020 --> Jun 2021 Suspended --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Jun 2019
- | Leukine (sargramostim) / Partner Therap
Biomarker, New P1 trial: Biomarker Assessments of Leukine During Treatment of Parkinson's Disease (clinicaltrials.gov) - Jan 2, 2019
P1, N=5, Not yet recruiting, Sponsor: University of Nebraska
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - Dec 28, 2018
P2, N=40, Active, not recruiting, Sponsor: University of Colorado, Denver
Suspended --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Jun 2019 Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Feb 2019
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial: NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Dec 26, 2018
P2, N=45, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Enrollment open, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov) - Dec 21, 2018
P1/2, N=90, Recruiting, Sponsor: Sellas Life Sciences Group
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Feb 2019 Not yet recruiting --> Recruiting
- |||| Zeltherva (galinpepimut-S) / SELLAS Life Sciences
New P1/2 trial, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov) - Dec 16, 2018
P1/2, N=90, Not yet recruiting, Sponsor: Sellas Life Sciences Group
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 14, 2018
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2018 --> Jun 2019
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
Trial completion date, Trial primary completion date: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Dec 14, 2018
P3, N=774, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2018 --> Jun 2019 Trial completion date: Mar 2022 --> Jun 2026 | Trial primary completion date: Mar 2022 --> Jun 2026
- | Leukine (sargramostim) / Partner Therap, FR Alpha Peptide Vaccine / National Cancer Institute
Trial completion date: Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer (clinicaltrials.gov) - Dec 14, 2018
P2, N=280, Recruiting, Sponsor: Academic and Community Cancer Research United
Trial completion date: Mar 2022 --> Jun 2026 | Trial primary completion date: Mar 2022 --> Jun 2026 Trial completion date: Jul 2021 --> Jul 2023
- | Leukine (sargramostim) / Partner Therap
New P4 trial: GRACE: GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study (clinicaltrials.gov) - Dec 9, 2018
P4, N=120, Recruiting, Sponsor: Nationwide Children's Hospital
- || Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Enrollment closed: Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (clinicaltrials.gov) - Dec 7, 2018
P2, N=100, Active, not recruiting, Sponsor: Cancer Insight, LLC
Trial completion date: Jul 2021 --> Jul 2023 Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Trial completion date: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Dec 4, 2018
P1, N=7, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: Sep 2018 --> Jan 2019
- | Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion, Trial completion date, Trial primary completion date: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Nov 30, 2018
P2, N=22, Completed, Sponsor: Sellas Life Sciences Group
Trial completion date: Sep 2018 --> Jan 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Feb 2018
- | Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Trial completion, Trial completion date, Trial primary completion date: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Nov 27, 2018
P2, N=300, Completed, Sponsor: George E. Peoples
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Feb 2018 | Trial primary completion date: Dec 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Sep 2018 | Trial primary completion date: Jun 2019 --> Sep 2018
- | Leukine (sargramostim) / Partner Therap
Enrollment change, Trial withdrawal: Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma (clinicaltrials.gov) - Nov 26, 2018
P2, N=0, Withdrawn, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Sep 2018 | Trial primary completion date: Jun 2019 --> Sep 2018 N=30 --> 0 | Recruiting --> Withdrawn
- | humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial completion: Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma (clinicaltrials.gov) - Nov 15, 2018
P1, N=34, Completed, Sponsor: St. Jude Children's Research Hospital
N=30 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- | Sitoiganap (ERC1671) / Epitopoietic Research Corp
Trial completion date, Trial primary completion date: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (clinicaltrials.gov) - Nov 15, 2018
P2, N=84, Recruiting, Sponsor: Daniela A. Bota
Active, not recruiting --> Completed Trial completion date: Mar 2019 --> Mar 2023 | Trial primary completion date: Mar 2019 --> Mar 2023
- | Leukine (sargramostim) / Partner Therap
Phase classification: Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Oct 31, 2018
P1, N=45, Completed, Sponsor: Mayo Clinic
Trial completion date: Mar 2019 --> Mar 2023 | Trial primary completion date: Mar 2019 --> Mar 2023 Phase classification: P=N/A --> P1
- | Leukine (sargramostim) / Partner Therap
Phase classification, Metastases: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Oct 31, 2018
P1, N=11, Completed, Sponsor: Mayo Clinic
Phase classification: P=N/A --> P1 Phase classification: P=N/A --> P1
- | Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion, Trial completion date: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Oct 12, 2018
P2, N=73, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P1 Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> Jun 2018
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Oct 4, 2018
P2, N=340, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> Jun 2018 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date, Immunomodulating: GM-CSF for Immunomodulation Following Trauma (GIFT) Study (clinicaltrials.gov) - Oct 1, 2018
P4, N=200, Recruiting, Sponsor: Mark Hall
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Leukine (sargramostim) / Partner Therap
Trial termination: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - Sep 25, 2018
P2, N=4, Terminated, Sponsor: University of Florida
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Completed --> Terminated; Insufficient resources necessary for completion.
- | Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - Sep 19, 2018
P2, N=4, Completed, Sponsor: University of Florida
Completed --> Terminated; Insufficient resources necessary for completion. Recruiting --> Completed | N=25 --> 4 | Trial completion date: Feb 2020 --> Sep 2018 | Trial primary completion date: Feb 2020 --> Sep 2018
- | Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial primary completion date: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Sep 18, 2018
P2, N=73, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=25 --> 4 | Trial completion date: Feb 2020 --> Sep 2018 | Trial primary completion date: Feb 2020 --> Sep 2018 Trial primary completion date: Feb 2019 --> Jun 2018
- | Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change, Trial primary completion date: GRID: GM-CSF to Decrease ICU Acquired Infections (clinicaltrials.gov) - Sep 18, 2018
P3, N=166, Completed, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Feb 2019 --> Jun 2018 Recruiting --> Completed | N=488 --> 166 | Trial primary completion date: Sep 2018 --> Jun 2018
- | Leukine (sargramostim) / Partner Therap, MVI-816 / Madison Vaccines, Opdivo (nivolumab) / BMS
Enrollment open: NCI-2018-01474: pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer (clinicaltrials.gov) - Sep 18, 2018
P2, N=41, Recruiting, Sponsor: University of Wisconsin, Madison
Recruiting --> Completed | N=488 --> 166 | Trial primary completion date: Sep 2018 --> Jun 2018 Not yet recruiting --> Recruiting
- | Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Trial completion, Trial completion date: Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Sep 12, 2018
P2, N=17, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Oct 2017
- || Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open: MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - Sep 10, 2018
P1, N=24, Recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Oct 2017 Not yet recruiting --> Recruiting
- | Trial completion: NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders (clinicaltrials.gov) - Sep 6, 2018
P2, N=41, Completed, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 17, 2018
P2, N=35, Completed, Sponsor: Montefiore Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS (clinicaltrials.gov) - Aug 17, 2018
P2, N=26, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | N=75 --> 26 | Trial primary completion date: Oct 2017 --> Nov 2019
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Aug 14, 2018
P=N/A, N=45, Completed, Sponsor: Mayo Clinic
Enrolling by invitation --> Active, not recruiting | N=75 --> 26 | Trial primary completion date: Oct 2017 --> Nov 2019 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's
Trial primary completion date: VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Aug 7, 2018
P2, N=108, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Mar 2019 --> Sep 2019
- | BiovaxID (dasiprotimut-T) / National Cancer Institute, Accentia
Trial completion date: Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 3, 2018
P2, N=26, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2019 --> Sep 2019 Trial completion date: Jun 2019 --> Jun 2020
- || Zolinza (vorinostat) / Merck (MSD), Azedra (iobenguane I 131) / Lantheus, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Trial initiation date, Trial primary completion date: MIBG With Dinutuximab +/- Vorinostat (clinicaltrials.gov) - Aug 2, 2018
P1, N=24, Not yet recruiting, Sponsor: New Approaches to Neuroblastoma Therapy Consortium
Trial completion date: Jun 2019 --> Jun 2020 Trial completion date: Dec 2021 --> Mar 2022 | Initiation date: May 2018 --> Sep 2018 | Trial primary completion date: May 2021 --> Sep 2021
- | Leukine (sargramostim) / Partner Therap, MVI-816 / Madison Vaccines, Opdivo (nivolumab) / BMS
New P2 trial: NCI-2018-01474: pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer (clinicaltrials.gov) - Jul 26, 2018
P2, N=41, Not yet recruiting, Sponsor: University of Wisconsin, Madison
- | Recentin (cediranib) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Jul 19, 2018
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2021 --> Mar 2022 | Initiation date: May 2018 --> Sep 2018 | Trial primary completion date: May 2021 --> Sep 2021 Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- | Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment closed, Enrollment change, Combination therapy: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors (clinicaltrials.gov) - Jul 18, 2018
P1, N=6, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Active, not recruiting | N=21 --> 6
- | Leukine (sargramostim) / Partner Therap, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change, Trial termination, Metastases: PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - Jul 12, 2018
P2, N=10, Terminated, Sponsor: Medical University of South Carolina
Recruiting --> Active, not recruiting | N=21 --> 6 N=25 --> 10 | Completed --> Terminated; Pharmaceutical collaborator pulled funding.
- | Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Trial completion date: Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 29, 2018
P2, N=17, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=25 --> 10 | Completed --> Terminated; Pharmaceutical collaborator pulled funding. Trial completion date: Mar 2018 --> Mar 2019
- | Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Jun 28, 2018
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2018 --> Mar 2019 Trial primary completion date: Jun 2018 --> Jun 2019
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 19, 2018
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2018 --> Jun 2019 Trial primary completion date: Nov 2013 --> Dec 2018
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial primary completion date: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jun 19, 2018
P2, N=64, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Nov 2013 --> Dec 2018 Trial primary completion date: Jun 2018 --> Sep 2018
- || temozolomide / Generic mfg.
Trial completion, Immunomodulating: GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) - Jun 18, 2018
P1, N=16, Completed, Sponsor: immatics Biotechnologies GmbH
Trial primary completion date: Jun 2018 --> Sep 2018 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change, Metastases: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Jun 8, 2018
P=N/A, N=11, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=23 --> 11